Are GLP-1 and weight-loss programs profitable for a practice?

The biggest revenue line is rarely the biggest profit line

GLP-1 weight-loss programs have become one of the fastest-growing offerings in cash-pay medicine, and for good reason: demand is enormous, patients pay out of pocket, and the monthly billing creates recurring revenue most practices never had before. On a revenue report, a GLP-1 program can quickly become the single largest line in the practice. That is exactly what makes it dangerous to read at face value.

The trap is structural. A large share of what the patient pays is not your margin at all; it is the cost of the medication itself, passing straight through your books to the pharmacy or supplier. The program can dominate revenue while contributing far less to profit than its size suggests. To know whether a GLP-1 program is actually profitable, you have to separate the drug from the service, and then look at what the service earns for the provider and staff time it consumes.

Where the money actually goes: pass-through vs. margin

Start by splitting the patient's monthly payment into two very different things. One part is the medication, which is a direct, variable cost you incur whether or not you ever see the patient again. The other part is everything the practice does around the medication: the consult, the titration, the monitoring, the messaging, the program structure. The first part is mostly pass-through. The second part is where a practice earns.

Compounded semaglutide and tirzepatide have been a large part of why these programs scaled so fast on a cash basis, because the per-dose cost to the practice could be far lower than branded equivalents. It is important to be honest here: the availability, sourcing, and pricing of compounded GLP-1 medications are volatile and depend heavily on regulatory conditions that have shifted and may shift again. Treat any drug-cost figure as a snapshot, not a permanent fact, and build your program so it survives a change in what you can source and at what price.

If the medication is most of the price, then the medication is most of the risk and almost none of the durable margin. The part of the program you control, and the part that keeps paying, is the service wrapped around the dose.

Here is the shape of it with illustrative, conservative numbers. Suppose a program charges roughly $349 per month, all-in. The medication for that month costs the practice somewhere in a wide and moving range; call it roughly $200 for the illustration. That single line is about 57 percent of the price. Before you have paid for a minute of provider time, more than half of the revenue is already spoken for. Whether the real number is higher or lower in your case, the lesson holds: do not mistake the top line for what you keep.

What the recurring visit really costs in time

The second cost is labor, and it is the one owners most often underweight. A GLP-1 program is not a single transaction; it is a series of recurring touchpoints. There is an initial intake, which is the longest and most clinical visit. Then there are the monthly or every-few-weeks check-ins during titration, where the dose steps up and side effects are managed. Then, for patients who stabilize, there is a lighter maintenance cadence that can stretch out over many months.

• Intake. The most provider-intensive visit: history, screening, goal-setting, and the first prescription. Illustratively 30 to 45 minutes of provider time, sometimes more.
• Titration check-ins. Shorter recurring visits, often 10 to 20 minutes, to step the dose, confirm tolerance, and adjust. These repeat for the first several months and are the heart of the recurring model.
• Maintenance. Once a patient is stable, the visit can be brief, illustratively 10 minutes or a quick asynchronous check, often delegable to lower-cost qualified staff.
• Between-visit work. Messages, refill coordination, side effect questions, and supply logistics. This is real labor that rarely shows up on any visit clock, and it accumulates across a full panel.

The reason this matters: the medication cost is fixed per month, but the labor cost is what you can actually move. A program that runs every visit through your most expensive provider will earn very differently from one that reserves the provider for intake and titration and shifts steady-state maintenance to a nurse, an RN, or an NP at a lower loaded cost. Same price to the patient, very different profit.

Putting it together: profit per provider-hour

The cleanest way to see whether the program is worth the time it eats is the same metric every cash-pay service should be measured by: profit per provider-hour. Take the monthly revenue, subtract the pass-through medication cost and the direct cost of the time spent that month, then divide by the provider-hours that month actually consumed. For a recurring model, run it on a steady-state maintenance month, because that is the state most of your panel lives in.

Monthly contribution = membership fee minus medication cost minus direct cost of provider and staff time

Work a maintenance month with the illustrative figures. The membership is $349. The medication is about $200. Suppose the maintenance visit plus the between-visit work comes to about 15 minutes of provider time, and that provider's loaded cost is about $120 per hour, so 0.25 hours costs roughly $30. That leaves:

1. Membership fee: $349
2. Less medication (pass-through): $200, leaving $149 of gross before labor
3. Less provider time, 0.25 hours at $120 per hour: $30
4. Monthly contribution: $349 minus $200 minus $30 = $119 per member that month

Now convert that to profit per provider-hour. The month used 0.25 provider- hours and contributed $119, so the program is earning $119 divided by 0.25 = $476 per provider-hour in steady state. That is a respectable number, and it is the number worth defending. Notice what produced it: not the drug, which netted nothing on its own, but the thin slice of provider time spread across a recurring fee. The economics live in the recurrence, not the dose.

Watch what happens if you run that same maintenance visit through a provider whose loaded cost is $200 per hour instead of $120. The time cost rises to $50, the monthly contribution drops to $99, and profit per provider-hour falls to $99 divided by 0.25 = $396. Same patient, same price, same drug; a worse result purely because of who delivered the visit. That single lever is often the difference between a program that funds the practice and one that just looks big. If you want the full method, see how to calculate profit per provider-hour.

Why a big GLP-1 line can still net little

Put the two failure modes together and you can see how a program becomes the practice's largest revenue line while quietly contributing little. First, the pass-through problem: if you price close to drug cost to win on price, the gross before labor is too thin to survive any provider time at all. Second, the labor problem: if every visit runs through an expensive provider with no delegation, the time cost eats what little gross remained.

This is the same pattern as a busiest service that is losing money: high volume disguising thin per-hour economics. It is also the reason revenue can climb while profit falls. A GLP-1 program is especially prone to it because the drug cost scales one- for-one with every patient you add, so growth does not dilute the biggest cost the way it does for a device-based service. Adding patients adds drug spend in lockstep. The only parts that scale in your favor are the fee and the labor efficiency, which is exactly where the levers are.

The levers: price the program, not the drug

If the medication is mostly pass-through and the recurring service is where you earn, then your decisions should follow that logic. Three levers move the number, and none of them depend on sourcing a cheaper dose.

1. Price the program, not the milligrams

Resist framing the fee as the drug plus a markup, because that anchors the patient on dose cost and erodes the moment your sourcing changes. Price the membership as a comprehensive program: provider oversight, titration, monitoring, and access. The fee should cover the medication and clear a target contribution for the time involved, the same way you would set any membership price from the recurring bundle of provider time it represents, not from the cheapest line item in it. This also insulates you when drug economics shift, which the compounded-medication landscape has repeatedly shown they can.

2. Shift maintenance to lower-cost staff

Reserve your highest-cost provider for the work that genuinely requires them, intake and active titration, and move stable maintenance to an RN, NP, or a well-designed asynchronous check-in within your scope and state rules. As the worked example showed, the same visit at a lower loaded cost can lift profit per provider-hour meaningfully without touching the price. Across a full panel of recurring members, that delegation is one of the largest profit levers you have.

3. Tighten the management overhead

The between-visit work, messaging, refill coordination, supply logistics, is the silent labor that turns a clean per-visit margin into a messy one. Systematize it: structured check-in templates, batched refills, clear protocols for common side effect questions, and software that reduces the manual handling per member. Each of these shaves minutes that, multiplied across the panel, are the difference between a program that scales profitably and one that drowns your staff as it grows.

For how this slots into the rest of your menu, see which of your cash-pay services actually make money, and use the add, keep, fix, or cut lens in how to know if a service is worth offering to decide what role GLP-1 should play in your practice.

So, is a GLP-1 program profitable?

It can be, and for many practices it is, but not for the reason owners usually assume. It is not profitable because of the medication; the drug is mostly pass-through and carries the most risk. It is profitable when the recurring fee is priced to clear a real contribution for the provider time it consumes, when maintenance is delivered by the lowest appropriate-cost staff, and when the management overhead is tight enough that the margin survives at scale. Run the steady-state month, measure profit per provider- hour, and you will know which version of the program you actually have.

The clearest way to see this is on a complete practice rather than one line. The Inside Look walks through a sample practice that looks healthy from the top, ranks every service, including recurring programs, by profit per provider-hour, and lets you re-price a membership, reassign the provider on a visit type, or change the cadence in an interactive forecaster and watch profit move, without adding a single patient. If a GLP-1 program is your largest revenue line, it is the line you most need to see clearly; start with why financial clarity is the difference between a busy program and a profitable one.